Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation

LW Newsfeed

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation.

image_printPrint Page

Conversation